Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNB4 | O00305 | 4/20 | 0.39 |
| ▸ | CACNA1A | O00555 | 4/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.39 |
| ▸ | CACNG3 | O60359 | 4/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 4/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.39 |
| ▸ | CACNB3 | P54284 | 4/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.39 |
| ▸ | CACNG7 | P62955 | 4/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 4/20 | 0.39 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.39 |
| ▸ | CACNG1 | Q06432 | 4/20 | 0.39 |
| ▸ | CACNB2 | Q08289 | 4/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 4/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.39 |
| ▸ | CACNA1E | Q15878 | 4/20 | 0.39 |
| ▸ | CACNA2D4 | Q7Z3S7 | 4/20 | 0.39 |
| ▸ | CACNA2D3 | Q8IZS8 | 4/20 | 0.39 |
| ▸ | CACNG8 | Q8WXS5 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11086354 | 0.85 | SLC22A12 (0.46) | L3MBTL1SLC22A12MAP3K5 | |
| SCHEMBL13539150 | 0.82 | PGR (0.48) | PGRRORARORCRORB | |
| SCHEMBL16729587 | 0.82 | PTGDR2 (0.44) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL15704178 | 0.81 | LMNA (0.42) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL15704208 | 0.81 | KRAS (0.44) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL24824798 | 0.81 | CYP19A1 (0.44) | KDM4EL3MBTL1HTR6ALDH1A1MAPT | |
| SCHEMBL10655507 | 0.81 | CACNB4 (0.47) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL16727205 | 0.81 | PTGER4 (0.43) | KDM4EHSD17B10L3MBTL1LMNAALDH1A1 | |
| SCHEMBL15704199 | 0.81 | CACNB4 (0.41) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL29200982 | 0.81 | KDM4E (0.47) | KDM4EHSD17B10LMNAHTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181245-B2 | Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease | Janssen Pharmaceuticals, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181245-B2 | Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease | Janssen Pharmaceuticals, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | CELLZOME LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | CELLZOME LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-7648738-B2 | for photopolymerization; photography, relief imaging; color filters | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2010-01-19 | — | — | US | disclosed |
| US-7648738-B2 | for photopolymerization; photography, relief imaging; color filters | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1567518-B1 | OXIME ESTER PHOTOINITIATORS WITH HETEROAROMATIC GROUPS | CIBA HOLDING INC (CH) | 2009-01-14 | — | — | EP | disclosed |
| US-4443615-A | ANILINE, GLYCOL OR EPOXIDE, SILICA AND/OR ALUMINA CATALYST | TANABE SEIYAKU CO., LTD. (JP) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | BACE1, PSEN1, BACE2 | CACNB4 1722/4885CACNA1A 487/4885CACNA1G 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.